These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34327623)

  • 1. CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study.
    Jiang Z; Dong Y; Yang L; Lv Y; Dong S; Yuan S; Li D; Liu L
    J Digit Imaging; 2021 Oct; 34(5):1073-1085. PubMed ID: 34327623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
    Lim CH; Koh YW; Hyun SH; Lee SJ
    Anticancer Res; 2022 Dec; 42(12):5875-5884. PubMed ID: 36456151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
    Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
    Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
    Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X
    Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting programmed death-ligand 1 expression level in non-small cell lung cancer using a combination of peritumoral and intratumoral radiomic features on computed tomography.
    Shiinoki T; Fujimoto K; Kawazoe Y; Yuasa Y; Kajima M; Manabe Y; Ono T; Hirano T; Matsunaga K; Tanaka H
    Biomed Phys Eng Express; 2022 Feb; 8(2):. PubMed ID: 35051908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients.
    Bracci S; Dolciami M; Trobiani C; Izzo A; Pernazza A; D'Amati G; Manganaro L; Ricci P
    Radiol Med; 2021 Nov; 126(11):1425-1433. PubMed ID: 34373989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
    Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
    Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CT-Based Weighted Radiomic Score Predicts Tumor Response to Immunotherapy in Non-Small Cell Lung Cancer].
    Zhu ZC; Chen MJ; Song L; Wang JH; Hu G; Han W; Tan WX; Zhou Z; Sui X; Song W; Jin ZY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Oct; 45(5):794-802. PubMed ID: 37674467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
    Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer.
    Xu T; Liu X; Chen Y; Wang S; Jiang C; Gong J
    BMC Med Imaging; 2024 Jul; 24(1):196. PubMed ID: 39085788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
    Chen M; Lu H; Copley SJ; Han Y; Logan A; Viola P; Cortellini A; Pinato DJ; Power D; Aboagye EO
    J Thorac Oncol; 2023 Jun; 18(6):718-730. PubMed ID: 36773776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
    Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Nogova L; Araceli T; Schmidt NO; Ruge MI; Goldbrunner R; Proescholdt M; Grau S; Lohmann P
    J Neurooncol; 2023 Jul; 163(3):597-605. PubMed ID: 37382806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
    Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
    J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The radiomic biomarker in non-small cell lung cancer:
    Wang YB; He X; Song X; Li M; Zhu D; Zhang F; Chen Q; Lu Y; Wang Y
    Clin Radiol; 2023 Oct; 78(10):e732-e740. PubMed ID: 37419772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer.
    Zhu Z; Chen M; Hu G; Pan Z; Han W; Tan W; Zhou Z; Wang M; Mao L; Li X; Sui X; Song L; Xu Y; Song W; Yu Y; Jin Z
    Eur Radiol; 2023 Jun; 33(6):3918-3930. PubMed ID: 36515714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
    Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.
    Zheng X; Shao J; Zhou L; Wang L; Ge Y; Wang G; Feng F
    Ther Innov Regul Sci; 2022 Jan; 56(1):155-167. PubMed ID: 34699046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.